ESTRO 2024 - Abstract Book

S1879

Clinical - Mixed sites, palliation

ESTRO 2024

Amendola, Beatriz E, Mahadevan, Anand, Blanco Suarez, Jesus Manuel, Griffin, Robert J, Wu, Xiaodong, Perez, Naipy C, et al. An International Consensus on the Design of Prospective Clinical – Translational Trials in Spatially Fractionated Radiation Therapy for Advanced Gynecologic Cancer. Cancers (2022). 14, 4267. Doi: 10.1667/RADE-20 00038.1 Amendola, Beatriz E, Perez, Naipy C, Mayr, Nina A, Wu, Xiaodong, Amendola, Marco. Spatially Fractionated Radiation Therapy Using Lattice Radiation in Far-advanced Bulky Cervical Cancer: A Clinical and Molecular Imaging and Outcome Study. Radiat. Res. (2020). 194, 724-736. Doi: 10.1667/RADE-20-00038.1 Duriseti Sai, Kavanaugh James, Goddu Sreekrishna, Price Alex, Knutson Nels, Reynoso Francisco, et al. Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors. Adv Radiat Oncol (2021). 6, 100639. Doi: 10.1016/j.adro.2020.100639. Yan, Weisi, Khan, Mohammad K, Wu, Xiaodong, Simone Charles B. II, Fan, Jiajin, Gressen, Eric, et al. Spatially fractionated radiation therapy: History, present and the future. Clin Transl Oncol (2020). 20, 30 – 38. Doi: 10.1016/j.ctro.2019.10.004

1027

Digital Poster

Pelvic Radiation Disease: Proactive Modification of Risk and Surveillance Post-Radiotherapy

Kirsty E Cavanagh 1 , Adam Peters 2 , Sally Darnborough 1 , Carol Smeaton 1 , Stephanie Millar 1 , Anthony Chalmers 2

1 Beatson West of Scotland Cancer Centre, Oncology, Glasgow, United Kingdom. 2 University of Glasgow, School of Cancer Sciences, Glasgow, United Kingdom

Purpose/Objective:

Pelvic radiation disease (PRD) is a condition with a wide clinical spectrum and documented impact on quality-of-life following treatment for cancer (1,2). Pelvic radiotherapy (RT) is a key treatment modality for gynaecological, gastrointestinal and urological cancers, both as a single agent and in combination with chemotherapy as a radio sensitiser. PRD is an important source of morbidity among cancer survivors, and specialist clinics have been shown to alleviate morbidity for some but not all patients. This study aimed to identify features associated with failure to benefit from intervention at a specialist clinic, in order to develop a risk categorisation model that could be used to inform prehabiliation and monitoring strategies for these patients.

Material/Methods:

Patients referred to a specialist PRD clinic were identified retrospectively, and clinical data was obtained from electronic records. Incidence was estimated from the number of patients referred to the PRD clinic against the total number of patients receiving pelvic RT for the various cancer subtypes over a 5-year time period . Gastrointestinal symptom rating scale (GSRS) scores were used to analyse changes in symptoms and quality of life (QoL) at baseline and at follow up. Where GSRS scores were not available, this data was estimated based on clinical records.